1. Introduction {#sec1}
===============

In daily clinical practice, dentists usually face alveolar bone loss problems caused by tooth extraction, severe periodontitis, or tumor surgery \[[@bib1], [@bib2]\]. The resulting bone defect not only hampers prosthetic reconstruction but also has an aesthetic effect in cases of periodontal defects. Therefore, bone surgery is performed to regenerate the lost bone and restore the alveolar ridge contour. Several grafting materials are used during surgery \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10]\].

The four basic categories of bone grafting materials are autograft, allograft, xenograft, and alloplastic graft. Autograft is still considered the gold standard because it provides a good scaffolding for osteoconduction and contains growth factors for osteoinduction as well as progenitor cells for osteogenesis. However, autograft procedures risk donor site morbidity and can be limited by graft availability. Allografts and xenografts risk disease transmission and can evoke an immunologic reaction \[[@bib11], [@bib12], [@bib13]\]. Due to these problems, there is an increasing interest in the use of alloplastic (synthetic) grafting materials.

The first documented use of a synthetic bone graft was reported in 1892 by Van Meekeren [@bib14], who treated a large bone defect with calcium sulfate. Since then, materials classified as bioceramics have been used extensively as bone graft substitutes in humans. The most widely used bioceramics material for bone grafting in humans is hydroxyapatite (HA) [@bib15], which has a chemical composition and crystalline structure similar to those of bone [@bib16].

HA and some other calcium-based ceramic materials can be regarded as bioactive materials since they have been reported to support bone ingrowth \[[@bib17], [@bib18], [@bib19]\]. Their bioactivity is related to their osteoconductive properties, which allow apposition and migration of osteoblasts at the material surface \[[@bib20], [@bib21]\]. HA is known to be able to bond directly to bone \[[@bib17], [@bib22]\]. HA, alone or combined with an auto/allo/xenograft, has been used with adequate clinical success rates in dentistry and maxillofacial surgery to support alveolar bone regeneration \[[@bib3], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26]\]. HA is available in a wide variety of forms (powders, porous blocks, or beads).

Several reviews on the use of HA as bone replacement graft to treat bone defects have already been reported \[[@bib27], [@bib28], [@bib29]\]. However, none has analyzed the bone regenerative effect of the HA bone substitute. Thus, the fundamental question of whether HA has significant clinical effect on alveolar bone regeneration remains unclear. Therefore, we determined and analyzed structurally the effect of HA bone substitute on alveolar bone regeneration in the case of ridge preservation, sinus augmentation, and periodontal bone defect treatment. For this purpose, all clinical HA applications for these three dental applications were considered.

2. Materials and methods {#sec2}
========================

The method of this systematic review is based on the guidelines of the Preferred Reporting of Systematic Review and Meta-Analysis (PRISMA) statement and modified from previous reviews \[[@bib30], [@bib31]\]. The format was followed according to the focused question approach called Population, Intervention, Comparison, and Outcomes (PICO). The focused question was "Is HA bone substitute effective in alveolar bone regeneration?"

2.1. Population, intervention, comparison, and outcomes {#sec2.1}
-------------------------------------------------------

All studies involving healthy individuals, without any age limit, who underwent any type of alveolar ridge or socket preservation, sinus augmentation, and periodontal bone defect treatment were included in the systematic review. Only studies involving a comparison between test (treatment using alloplastic material based on HA) and control (unassisted socket healing; autograft; allograft; xenograft; socket sealing, such as soft tissue graft; membrane barrier; biological active agent, such as platelet-rich plasma \[PRP\]; growth factor; or a combination of the above techniques/materials) groups were included. When the treatment outcomes in the studies were related to alveolar bone regeneration (clinically, radiographically, histologically, and histomorphometrically), the studies were included in the systematic review.

For further consideration in this systematic review, a variety of outcome measures of interest could be considered to assess the effectiveness of HA-based material for alveolar bone regeneration. For this systematic review, studies were included when the primary outcome measure was: (1) radiographic assessment: changes in bone density or changes in bone volume; and (2) histologic and histomorphometric assessment: formation of new alveolar bone in the defect area. In addition, secondary outcome measures were also considered in some studies, which included clinical assessment, such as periodontal pocket depth (PPD), clinical attachment level (CAL), bleeding on probing, plaque index (PI), and gingival index (GI).

2.2. Search strategy {#sec2.2}
--------------------

Electronic databases were used to search literature for articles published from 1981 up to and including August 2015. The search was performed using MEDLINE via PUBMED, EMBASE, and Cochrane databases. A combination of search terms (key words and MeSH terms) was used to identify the proper studies, including hydroxyapatite OR hydroxy apatite OR apatite OR calcium hydroxyapatite OR hydroxyapatite-bioglass OR nano-hydroxyapatite OR hydroxyapatite cement OR coralline hydroxyapatite AND bone regeneration OR bone healing OR bone response OR osseointegration AND ridge preservation OR periodontal defect OR alveolar bone defect OR sinus augmentation OR maxillary sinus augmentation OR sinus floor augmentation OR extraction site OR implant site.

2.3. Eligibility criteria for study inclusion {#sec2.3}
---------------------------------------------

The selection was limited to English language-only human studies related to alveolar bone treatment. Longitudinal prospective studies (randomized \[RCTs\] and clinical \[CCTs\] controlled trials) were included [@bib31].

Additional inclusion criteria were all human trials involving healthy individuals without any age limits who underwent treatment related to alveolar bone (ridge or socket preservation, sinus augmentation, and periodontal bony defect). Among them, only studies reporting at least five patients with at least 3 months of follow-up were analyzed. Studies using outcome measures related to bone regeneration (either clinical, radiographic/histologic, and histomorphometric) were included for further review. The exclusion criteria were (1) case reports, case series, and/or case control analyses; (2) studies without a control group; (3) studies without any comparison between the use of the alloplastic material and another treatment; and (4) in vitro, animal, and no clinical control studies (literature review/systematic review).

2.4. Data extraction and statistical analysis {#sec2.4}
---------------------------------------------

Each study was evaluated independently by two readers (A.H.D. and I.D.A). Disagreements were resolved by discussion. The level of agreement between the reviewers was determined by κ value. The data were extracted based on general characteristics (treatment modality, study design, and outcome measure). Means and standard deviations (SD) from each study were used to calculate 95% confidence intervals (CI) [@bib32]. Statistical analysis was performed with SPSS for Window v.15 (SPSS, Inc., Chicago, IL, USA). Furthermore, results of studies that used the same methods of evaluation and similar outcome measurements were combined and the data were presented in a statistical graph.

2.5. Quality assessment {#sec2.5}
-----------------------

To evaluate the methodologic quality and risk of bias, we used parameters combined from the Cochrane Collaboration and Consolidate Standards of Reporting Trials statement and previous studies \[[@bib32], [@bib33]\]. The following parameters were assessed in some studies, such as RCTs and CCTs: adequate sequence generation, allocation concealment, randomization method, masking, statement of eligibility criteria (inclusion and exclusion), follow-up, method of statistic (sample size calculation/power of statistic), and risk of bias category (low/moderate/high).

Randomization was accepted as adequate when the case allocation sequence was generated by referring to a random table (using a computer or tossing a coin or shuffling cards or envelopes). On the other hand, randomization was considered inadequate if the case allocation sequence was generated by odds or based on the date of birth, date of admission, or hospital/clinical record number. Adequate allocation concealment was further accepted if participant and investigator could not foresee assignments before assigning a subject to a group. Studies were considered as having adequate concealment before the intervention if the intervention was concealed using central telephone, web-based, pharmacy-controlled, and/or sequentially numbered drug containers in sealed opaque envelopes until the intervention was assigned.

Studies were considered qualified if they applied adequate statistical analysis and had low risk of bias. Statistical analysis was judged adequate if the reported group number, size of sample, normal distribution, parametric or nonparametric, and power of statistic (*P* value) data were available. The categories of risk of bias were divided into low, moderate, and high risk based on quality assessment. Low risk of bias was classified if the following criteria were clearly met in the study: adequate sequence generation with adequate allocation concealment as well as applied masking for participant and examiner with reported eligibility criteria and detailed report for the follow-up. Moderate and high risk of bias was considered if one and more than one criteria for risk of bias were lacking, respectively \[[@bib31], [@bib33]\].

3. Results {#sec3}
==========

The MEDLINE literature search resulted in 504 articles. After the first step selection based on the title of the collected studies, 242 articles were included for further steps (inter-reader agreement, κ = 0.968). Step 2, based on abstract screening, resulted in 74 studies (inter-reader agreement, κ = 0.910). From these 74 studies, 42 completely fulfilled the inclusion criteria in the final step (inter-reader agreement, κ = 0.864), while 32 were excluded ([Table 1](#tbl1){ref-type="table"}) for reasons shown in [Table 2](#tbl2){ref-type="table"}. [Table 3](#tbl3){ref-type="table"} shows the quality assessment for the overall treatment modalities (alveolar ridge or socket preservation, sinus augmentation, and periodontal bone defect) in the 42 included studies. [Table 3](#tbl3){ref-type="table"} also presents the outcomes of the study quality assessment for RCTs and CCTs study designs. From the 42 studies, three, one, and 38 were classified as having low, moderate, and high risk of bias, respectively.Table 1Selection of publications.Table 1StepsNumber of articlesNotesSearched by MEDLINE Search via Pubmed EMBASE and Cochrane Database504Articles published by August 2015Applied first selection: Human trials241κ value: 0.968Screened by abstracts74κ value: 0.910 Included by inclusion criteria42κ value: 0.864 Excluded by exclusion criteria32Referred to [Table 2](#tbl2){ref-type="table"}Used for further analysis42 With similar outcome measures to be analyzed statistically17 Without similar outcome measures; Not allowing statistical analysis25Table 2Reason for exclusion.Table 2No.StudyReason for exclusionNo.StudyReason for exclusion1Singh A et al., 2014 [@bib34]Only one patient17Cook DC et al., 2013 [@bib35]Not comparing a synthetic bone substitute2Coathup MJ et al., 2015 [@bib36]Treatment not for alveolar bone18Menezes LM et al., 2012 [@bib37]Not comparing a synthetic bone substitute3Kato E et al., 2015 [@bib38]Outcome measure not related to alveolar bone regeneration19Horvarth A et al., 2013 [@bib39]Not comparing a synthetic bone substitute4Gupta G et al., 2014 [@bib40]Not comparing a synthetic bone substitute20Ghanaati S et al., 2013 [@bib25]Control group not available5Troedan A et al., 2014 [@bib41]Outcome measure not related to alveolar bone regeneration21Pietruska M et al., 2012 [@bib42]Outcome measure not related to alveolar bone regeneration6Reichert C et al., 2014 [@bib43]Outcome measure not related to alveolar bone regeneration22Emam H et al., 2011 [@bib44]Not comparing a synthetic bone substitute and control group not available7Cosso MG et al., 2014 [@bib3]Not comparing a synthetic bone substitute23Lee CY et al., 2011 [@bib45]Not comparing a synthetic bone substitute8Ghanaati S et al., 2014 [@bib46]Outcome measure not related to alveolar bone regeneration24Mairoana C et al., 2011 [@bib47]Not comparing a synthetic bone substitute and control group not available9de Ruiter A et al., 2014 [@bib4]Control group not available25Caubet J et al., 2011 [@bib48]Control group not available10Traini T et al., 2015 [@bib49]Control group not available26Goene RJ et al., 2007 [@bib50]Outcome measure not related to alveolar bone regeneration11Gupta S et al., 2013 [@bib51]Not comparing a synthetic bone substitute27Pappalardo S et al., 2005 [@bib52]Only one patient12Cannizaro G et al., 2013 [@bib53]Outcome measure not related to alveolar bone regeneration28Nemcovsky CE et al., 2001 [@bib54]Not comparing a synthetic bone substitute13Peres MF et al., 2013 [@bib55]Not comparing a synthetic bone substitute29Fugazzotto PA et al., 1999 [@bib56]Only one patient14Pieri F et al, 2013 [@bib57]Control group not available30Wheeler SL et al., 1996 [@bib58]Not comparing a synthetic bone substitute15Kim DM et al., 2013 [@bib59]Not comparing a synthetic bone substitute31Galgut PN et al., 1992 [@bib60]Outcome measure not related to alveolar bone regeneration16Corinaldesi G et al., 2013 [@bib61]Not comparing a synthetic bone substitute32Hurzeler MB et al., 1996 [@bib62]Outcome measure not related to alveolar bone regenerationTable 3Quality assessment for all treatment modalities (modified from Plachokova et al., 2008 [@bib32] and Vignoletti, 2011 [@bib33]).Table 3Quality assessment itemsYes/noAlveolar ridge or socket preservationSinus augmentationPeriodontal bony defectAdequate sequence generationY147N51213Allocation concealmentY144N51216Describe as randomizedY31216N344Describe clear randomization methodsY226N41414Describe control groupY61620N000Blinding participant and/or examinerY235N41315Describe inclusion and exclusion criteriaY21214N446Patient follow-up related to completed outcome dataY51116N154Validity of statistical methods: sample calculationY184N5816Validity of statistical methods: power of statisticY41218N242Validity of outcome and estimationY61620N000Risk of bias: high51518Moderate001Low111Total**61620**

3.1. Alveolar ridge or socket preservation {#sec3.1}
------------------------------------------

For alveolar ridge or socket preservation, six studies involved RCTs \[[@bib1], [@bib63]\] and prospective CCTs \[[@bib2], [@bib64], [@bib65], [@bib66]\] that reported parallel [@bib65] or split mouth \[[@bib1], [@bib63]\] designs ([Table 4](#tbl4){ref-type="table"}). A number of participants (10--83 persons; age, 30--70 years) were divided into two to five study groups, with a follow-up of 4--24 months after grafting.Table 4Alveolar ridge or socket preservation with primary outcome measure related to new bone formation (mean ± SD, 95% CI, and *P* value).Table 4StudiesIntervention groupNMeasurement methodsFollow-up (month)Control groupTest groupPower of statisticShakibaie B 2013 (CCT)T1: Bio-Oss + gelatin sponge\
T2: NanoBone + gelatin sponge\
C: Stypro gelatin sponge11\
11\
103D DVT (bone density)10352 ± 29.3T1: 699 ± 13.3\
T2:399 ± 15.6NASisti A et al., 2012 (RCT)T: Mg-eHA + saline\
C: Guided bone regeneration10\
10CT (horizontal bone width)247.70 ± 0.929.48 ± 1.56*P*~val~ \< 0.05Rebaudi A et al., 2003 (CCT)T: Biostite (Containing HA)\
C: Naturally healingNA\
NA (83)Radiographic (radiopaque tissue over the implant) and histology4\
612%20%NAArenaz-búa J et al., 2010 (RCT)C1: Any material-PRP Method 1\
C2: Any material-PRP Method 2\
C3: Autologous + PRP Method 1\
C4: DBX + PRP Method 1\
T: Novabone (HA) + PRP Method 1NA\
NA\
NA\
NA\
NA (82)Digital panoramic3\
6Descriptive/No statistical analysis\
Bone formation after 3 months: groups C1, C2, C3 are higher and groups T and C4 are lower\
Bone formation after 6 months: groups C3, C4 are higher and group T is lower than the other groupLuczyszyn S M et al., 2005 (CCT)T: Resorbable HA (Algipore) + Acellular dermal matrix graft (ADMG)\
C: ADMGNA\
NA (11)Histology (newly formed bone)646%1%NADe Coster P et al., 2011 (CCT)T: Bone ceramic + Blood\
C: Natural healing (Untreated)14\
14Histology sectionDescriptive/no statistical analysis

The periodontal status of the extracted teeth was defined in one study [@bib1]. The teeth extraction area was clearly reported in three studies \[[@bib1], [@bib2], [@bib63]\]. Several kinds of HA bone substitutes, such as synthetic HA (NanoBone) [@bib2], Mg-eHA [@bib1], synthetic calcium HA (Novabone) [@bib63], resorbable HA (Algipore) [@bib65], and bone ceramic [@bib64], were used in the test groups. The control group used materials such as gelatin sponge [@bib2], acellular dermal matrix graft (ADMG) [@bib65], and autologous grafts [@bib63], in comparison with bone grafting material or extraction socket left untreated [@bib64]. Radiographs with three-dimensional (3D) digital volume tomography (DVT) [@bib2], cone beam computed tomographic (CT) scan [@bib1], and digital panoramic X-rays [@bib63] were used for analysis. Rebaudi et al. [@bib66] performed radiograph evaluation but they did not mention the method and instrument used to perform the evaluation. In three studies, bone regeneration was evaluated histologically \[[@bib64], [@bib65], [@bib66]\], but two of these studies \[[@bib63], [@bib64]\] were without statistical analysis. Based on the structural analysis, six studies reported that alveolar ridge or socket preservation was not allowed for further analysis. Thus, the effect of HA bone substitute on alveolar bone regeneration in the case of ridge preservation could not be determined.

3.2. Sinus augmentation {#sec3.2}
-----------------------

For sinus augmentation, 16 studies involved RCTs \[[@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib72]\] and prospective CCTs \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib22], [@bib24], [@bib73], [@bib74], [@bib75], [@bib76]\] that reported a parallel \[[@bib67], [@bib69], [@bib70]\] or split mouth \[[@bib68], [@bib75]\] design ([Table 5](#tbl5){ref-type="table"}). The study population included eight to 43 subjects (age, 18--80 years) divided in two to five study groups, with five to 12 months of follow-up after grafting. The outcome measures were analyzed by histomorphometry \[[@bib5], [@bib6], [@bib8], [@bib22], [@bib67], [@bib68], [@bib69], [@bib70], [@bib72], [@bib73], [@bib74], [@bib75]\], radiography by CT \[[@bib24], [@bib71], [@bib76]\], and histology [@bib7].Table 5Sinus augmentation with primary outcome measure related to new bone formation (mean ± SD, 95% CI, and *P* value).Table 5StudiesIntervention groupNMeasurement methodsFollow-up (month)Control group (C)Test group (T)Power of statisticSchmitt CM et al., 2013 (RCT)T: Biphasic calcium phosphate (BCP) with 60% HA14Histomorphometric (newly formed bone)5C1: 24.90 ± 5.67%\
C2: 35.41 ± 2.78%\
C3: 41.74 ± 2.10%T: 30.28 ± 2.16%*P* = 0.000 between T & C3C: Inorganic bovine bone (ABB)15C2: Bone allograft (MCBA)12C3: Autologous bone (AB)12Ghanaati S et al., 2013 (RCT)T: Synthetic HA (NanoBone)4Histomorphometric (newly formed bone)6C: 25.73 ± 7.94%T: 21.85 ± 5.96%*P* \> 0.05 (*P*~val~ \< 0.05)C: Deproteinized bovine bone (Bio-Oss)4Lezzi G et al., 2012 (CCT)T1: Phycogene HA (Algipore)6Histomorphometric (newly formed bone)6C1: 31.8 ± 2.9%\
C2: 32.9 ± 0.5%T1: 33.2 ± 1.2%\
T2: 30.5 ± 3.4%\
T3: 28.1 ± 3.9%*P* \< 0.05 (*P*~val~ \< 0.05)T2: Macroporous biphasic CaPO~4~ (MBCP)6T3: Calcium carbonate (Biocoral)6C1: Collagenized porcine cortical/cancellous bone (Apatos)6C2: Inorganic bovine bone (ABB)6Kurkcu M et al., 2012 (CCT)T: β-Tri calcium phosphate or β-TCP (Kasios)13Histomorphometric (newly formed bone)6.530.13 ± 3.45%21.09 ± 2.86%*P* = 0.001 (*P*~val~ \< 0.05)C: Inorganic bovine derivate HA (Bone Plus-XS)13Lorenz J. et al., 2014 (CCT)T: Synthetic HA (NanoBone)7Histomorphometric (nexwly formed bone)722.66 ± 7.97%19.02 ± 7.28%*P* \> 0.05 (*P*~val~ \< 0.05)C: Deproteinized bovine bone (Bio-Oss)7Lindrgen C et al., 2012 (RCT)T: Biphasic calcium phosphate (BCP)5Histomorphometric (newly formed bone)831.7 ± 18.0%28.6 ± 14.3%*P* = 0.67 (P~val~ \< 0.05)C: Deproteinized bovine bone (DBB)5Boeck-Neto RJ et al., 2001 (CCT)T: Autogenous + HA5Histomorphometric (newly formed bone)1050.46 ± 16.29%46.79 ± 8.56%NAC: Autogenous + DFDBA5Mangano C et al., 2007 (CCT)T: Porous synthetic HA20Histomorphometric (newly formed bone)1236.2 ± 1.4%34.7 ± 3.1%*P* = 0.031 (*P*~val~ \< 0.05)C: Bovine derivate HA20Artzi Z et al., 2001 (RCT)T: Synthetic nonceramic resorbable HA (NC-HA)14Histomorphometric (bone area fraction at 10 sites)1242.1 ± 10.0%32.2 ± 8.15%NAC: Natural deproteinized bovine HA (BHA)14Baena RR et al., 2013 (RCT)T: Polyacid-HA (PLGA/HA)4Radiographic by CT (bone density)6946 ± 161.9286 ± 134.4*P* = 0.002 (*P*~val~ \< .05)C: Deproteinized bovine bone4Tosta M et al., 2013 (RCT)T: Biphasic calcium phosphate (with 60% HA and 40% β-TCP) + Membrane collagen\
C: Particulate autogenous + Membrane collagen15\
15Histomorphometric (area fraction of mineralized bone)9Area 1:\
41.03 ± 4.62%\
Area 2:\
38.63 ± 7.52%Area 1:\
33.70 ± 8.08%\
Area 2:\
26.68 ± 3.92%*P1* = 0.008\
*P2* \< 0.001 (*P*~val~ \< 0.05)Lindgren C et al., 2010 (CCT)T: β-TCP + HA11Histological analysis\
EDS (Ca/P Ratio)81.72 ± 0.071.63 ± 0.02NAC: Deproteinized Bovine Bone11Karabuda C et al., 2001 (CCT)T: Porous HA (PHA)3Histomorphometric (newly formed bone)6C1: 70--75%\
C2: 50%20--35%NAC1: Demineralized freeze-dried bone powder (DFBP)1C2: Deproteinized bovine bone granule (DBBG)5Lorenzetti M et al., 1998 (CCT)T: Autogenous from chin + PHA (Interpore 200)3Histomorphometric (newly formed bone)8&12C1: 53%\
C2: 69.3%\
C3: 62.6%T: 44.3%NAC1: Autogenous from iliac4C2: Autogenous from chin3C3: Particulate autogenous3Kuhl S et al., 2012 (CCT)T: Blood + PAB + β-TCP10Radiographic by CT (bone density)NA\#C: 0.5\#T1: 0.08\
\#T2: 0.00031*P* = 0.341 (*P*~val~ \< 0.05)T: Blood + PAB + β-TCP/HA10C: Blood + PAB10Kuhl S et al., 2013 (CCT)T~1~: Blood + Autogenous Bone (PAB) + β-TCP10Radiographic by μ-CT (Volume fraction bone)518.5%T1: 17.1%\
T2: 21.7%*P* = 0.578T~2~: Blood + PAB + β-TCP/HA10C: Blood + PAB10

In the test group, biphasic calcium phosphate (BCP) containing 60% HA \[[@bib67], [@bib69], [@bib72], [@bib73]\], synthetic HA (NanoBone) \[[@bib68], [@bib75]\], HA bone substitute [@bib6], porous synthetic HA \[[@bib5], [@bib8], [@bib22]\], synthetic nonceramic HA (NC-HA) [@bib70], polyacid-HA (PLGA/HA) [@bib71], composites containing HA \[[@bib5], [@bib6], [@bib8], [@bib22], [@bib70], [@bib71], [@bib73], [@bib75]\], and inorganic bovine-derived HA \[[@bib7], [@bib24], [@bib74], [@bib76]\] were used. The materials applied in the test group were used either alone or combined with other materials. The control group for the studies on sinus augmentation used inorganic bovine \[[@bib7], [@bib8], [@bib22], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib73], [@bib74], [@bib75]\] and autologous \[[@bib5], [@bib6], [@bib24], [@bib72], [@bib76]\] bone as a comparison.

From 16 studies analyzing sinus augmentation-tested biomaterials containing HA, either alone or combined with another graft/autograft \[[@bib5], [@bib6], [@bib76]\], membrane collagen [@bib72], or the patient\'s own blood \[[@bib24], [@bib76]\], only eight could be compared to each other since they used the same measurement methods and reported mean, SD/standard error, or *P* values. [Fig. 1](#fig1){ref-type="fig"} shows comparison of the mean values and 95% CIs for the test and control groups of the eight selected comparable studies performed for treatment of sinus augmentation. The analysis confirmed that HA had an effect in alveolar bone regeneration when used for sinus augmentation treatment. Only a study by Schmitt [@bib67] shows no significant different between the treatments using biphasic calcium phosphate-containing HA compared to inorganic bovine bone.Fig. 1Comparison of the mean values and 95% confidence intervals for the test and control groups of the selected studies performed dealing with the treatment of sinus augmentation.Fig. 1

3.3. Periodontal bone defect {#sec3.3}
----------------------------

For periodontal bone defects ([Table 6](#tbl6){ref-type="table"}), 20 studies involving RCTs \[[@bib10], [@bib77], [@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib83], [@bib84], [@bib85]\] and prospective CCTs \[[@bib9], [@bib86], [@bib87], [@bib88], [@bib89], [@bib90], [@bib91], [@bib92], [@bib93], [@bib94]\] reported a parallel \[[@bib79], [@bib84], [@bib87]\] or split mouth \[[@bib10], [@bib81], [@bib83], [@bib86]\] design. The study population consisted of 12--263 persons (age, 14--75 years) divided into two to four study groups with a follow-up of 1--24 months after grafting. The outcome measures were analyzed radiographically by Intraoral Periapical (IOPA) \[[@bib10], [@bib78]\], CT [@bib86], long cone-paralleling technique \[[@bib80], [@bib85], [@bib91], [@bib94]\], computer assisted densitometry image analysis (CADIA) [@bib87], and other radiographic methods \[[@bib9], [@bib79], [@bib81], [@bib82], [@bib83], [@bib88], [@bib89], [@bib92], [@bib93]\].Table 6Periodontal bony pocket with primary outcome measure related to new bone formation (mean ± SD, 95% CI, and *P* value).Table 6StudiesIntervention groupNMeasurement methodsFollow-up (month)Control group (C)Test group (T)Power of statisticPradeep AR et al., 2016 (RCT)T1: Platelet-rich fibrin (PRF) + HA + Open flap debridement (OFD)Radiographic by intra oral periapical/IOPA (bone defect fill)910.09 ± 4.28%T1: 54.69 ± 1.93%\
T2: 61.94 ± 3.54%*P*~val~ \< 0.001T2: RSV gel + PRF + HA + OFD36C: OFD + Placebo gel37Debnath T et al., 2014 (RCT)T1: HA-BG (bioactive glass) + biodegradable membrane10Radiographic by intra oral periapical/IOPA (bone defect fill)60.9 ± 0.7%T1: 2.6 ± 0.66%\
T2: 1.6 ± 0.66%NAT2: HAP + biodegradable membrane10C: OFD + biodegradable membrane10Kumar PG et al., 2011 (CCT)T: Alloplast containing HA (Bonelike)10Radiograph CT (defect fill)637.41 ± 23.63 mm62.59 ± 31.58 mm*P* = .04C: OFD10Chandrashekar KT & Saxena KT, 2009 (RCT)T: Synthetic HA + β-TCP (Biograft HT)13Radiographic by the long cone-paralleling technique (defect fill)3\
64.200 ± 0.978\
3.800 ± 0.8623.667 ± 1.029\
2.633 ± 0.896*P* = 0.212\
*P* = 0.014\
(*P*~val~ \< 0.01)C: OFD13Brown GD et al., 1998 (CCT)T1 (2 defect): Flap & HAC8Radiographic by computer assisted densitometry image analysis/CADIA (defect fill)12Flap: 32.3 ± 23.8HAC: 29.2 ± 31.7\
DFDB: 41.9 ± 42.9(*P*~val~ \< 0.05)T2 (2 defect): DFDB + HAC16Leonardis DD et al., 2013 (RCT)T: EMD (enamel matrix derivative) + HA/β-TCP36Radiographic (bone gain)\#0--12\
\#0--24C1: 2.32 ± 0.40\
C2: 0.13 ± 0.48\
C1: 3.17 ± 0.69\
C2: 0.23 ± 0.55T: 2.61 ± 0.49\
T: 3.35 ± 0.80(*P*~val~ \< 0.001)C1: EMD36C2: OFD36Singhal et al., 2013T: OFD ± β-TCP/H + barrier membrane6Radiographic (bone defect area decreased)\#0--614.08 ± 12.7%48.88 ± 18.61*P* = 0.009C: OFD + barrier membrane6Singh VP et al., 2012 (RCT)T: nanocrystal (Nc-HA) + collagen membrane10Radiographic (defect fill gain changes)\#0--60.91 ± 0.212.07 ± 0.67*P*~control~ = 0.008\
*P*~test~ = 0.007C: OFD10Mistry S et al., 2012 (CCT)T1: OFD + HA8Radiographic (depth of the defect)6\
\#0--69.20 ± 0.44\
3.00 ± 0.71T1: 9.40 ± 1.51\
T2: 8.80 ± 0.83\
T3: 9.40 ± 1.51\
T1: 3.00 ± 0.71\
T2: 4.40 ± 1.14\
T3: 4.20 ± 0.44*P* \< 0.01T2: OFD + BG (Bioactive Glass)8T3: OFD + BG + HA8C: OFD8Assche NV et al., 2013 (RCT)T: Straumann bone ceramic14Radiographic (depth of defect changes)\#0--61.9 ± 1.21.5 ± 1.2*P* \> 0.05C: Bio-Oss14Pietruska M et al., 2012 (CCT)T: OFD + NHA15Radiographic (defect depth & defect width)\#0--6DD: 0.6 ± 0.9\
DW: 0.7 ± 0.8DD: 1.8 ± 1.5\
DW: 0.7 ± 0.9DD:\
*P*~val~ \< 0.05\
DW:\
*P*~val~ \< 0.001C: OFD15Lekovic V et al., 1990 (CCT)T: PHA + barrier membrane (Goretex)NAAcrylic stent (bone level)6Vertical bone level: 0.13 ± 0.26\
Horizontal Bone level: 0.13 ± 0.09Vertical bone level: 2.27 ± 0.18\
Horizontal Bone level: 1.60 ± 0.021*P*~val~ \< 0.01C: GoretexNA (15)StudiesIntervention groupNMeasurement methodsFollow-up (month)Control groupTest groupPower of statisticJepsen S et al., 2008 (RCT)T: EMD ± synthetic bone\
Ceramic (SBC)-HA\
C: EMD29\
29Bone sounding (defect fill)\#0--62.07 ± 1.2 mm2.01 ± 2.1 mm*P* \< 0.001Bowen J A et al., 1989 (CCT)T: particulate HA\
C: demineralized freeze cried bone allograft (DFDBA)6\
6Radiographic by paralleling device (bone defect fill)661%53%*P*~val~ \< 0.05Lai N & Dixit J 2012 (CCT)T: OFD + HA + own blood\
C1: OFD + Cissus Quadrangu laris (CQ) + saline\
C2: Oxidized regenerated + OFD\
C3: OFD5\
5\
5\
5Radiographic (defect fill)1\
3\
6C1: 1.6 mm^3^\
C2: 3 mm^3^\
C3: 0.60 mm^3^T: 3 mm^3^NATobon SI et al., 2002 (RCT)T1: periradicular surgery + resorbable HA (OsteoGen)\
C1: periradicular surgery + nonabsorbable membrane (e-PTFE)\
C2: periradicular surgery with Conventional technique8\
8\
8Radiographic by parallel technique (bone healing by size of lesion area)3\
6\
9\
12NANA*PT2* = 0.0002\
*PC1* = 0.002\
*PC2* = 0.1 (*P*~val~ ≤ 0.05)Harris RJ, 1998 (CCT)T: DFDB + PHA + tetracyclin\
C: DFDB + tetracyclin50\
50Radiographic (descriptive)10NAHorizontal probing depth reducing 7.0 mm--2.5 mmNAKiliq AR, 1997 (CCT)T1: e-PTFE membrane + HA +\
Collagen type 1\
T2: HAC\
C1: e-PTFE membrane\
C2: Conventional flap (CF)10\
10\
10\
10Radiographic by the parallel technique (bone level)6C1: 36%\
C2:15%T1: 43%\
T2: 23%NABowen JA et al., 1989 (CCT)T: Particulate HA\
C: DFDBA6\
6Radiographic by customized paralleling (defect fill)661%53%*P*~val~ \< 0.05Queiros L A et al., 2015 (RCT)T1: β-TCP/HA\
T2: Enamel matrix derivative (EMD) + β-TCP\
C: EMD13\
13\
13Clinically (PI/GI/RGMP/RVCAL/RHCAL/PPD) for soft tissue12Outcome measure only for soft tissue

The control groups underwent open flap debridement (OFD) \[[@bib9], [@bib10], [@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib86], [@bib88], [@bib89]\], demineralized freeze-dried bone allografts (DFDBA) \[[@bib87], [@bib91]\], bovine bone [@bib83], barrier membrane (Goretex) [@bib90], enamel matrix derivative (EMD) \[[@bib77], [@bib84]\], nonabsorbable polytetrafluoroethylene membrane (e-PTFE) [@bib85], and debridement only (DEBR) [@bib93]. The test groups were alloplastic graft alone with β-tricalcium phosphate (β-TCP/HA) [@bib77] and bonelike containing glass-reinforced HA [@bib86], synthetic HA alone [@bib93], porous HA (PHA) [@bib90], resorbable HA (Osteogen) [@bib66], or synthetic HA combined with OFD \[[@bib9], [@bib78], [@bib88], [@bib89]\], PRP [@bib78], β-TCP \[[@bib80], [@bib81], [@bib82]\], barrier membrane such as EMD \[[@bib81], [@bib84]\], collagen membrane [@bib79], Goretex [@bib90], e-PTFE membrane [@bib94], bioactive glass [@bib10], or DFDBA [@bib92]. The mean values and 95% CIs for the test and control groups of the selected comparable studies performed for treatment of periodontal bone defect measured in certain follow-up periods ([Fig. 2](#fig2){ref-type="fig"}) and based on the difference between the baselines and certain follow-up periods (Δ in [Fig. 3](#fig3){ref-type="fig"} were compared. There was no significant difference between the treatments of periodontal bony defect with HA compared to the controls.Fig. 2Comparison of the mean values and 95% confidence intervals for the test and control groups of the selected studies performed dealing with the treatment of periodontal bone defects.Fig. 2Fig. 3Comparison of the mean values and 95% confidence intervals for the test and control groups of the selected studies performed dealing with the treatment of periodontal bone defects.Fig. 3

4. Discussion {#sec4}
=============

We reviewed studies on the effect of HA bone substitute on three treatment modalities (i.e., ridge or socket preservation, sinus augmentation, and periodontal bony defect). Besides autologous bone as a gold standard, other graft sources, such as allograft (DFDBA or mineralized freeze-dried bone allograft), xenogenic (organic bovine, porcine, caprine, or coral-derived HA), replicating (morphogenetic proteins), and alloplastic (bioglass, bioceramics) graft materials or combinations, are available.

The present systematic review was limited to RCTs and CCTs. The control groups included patients who had autogenous, allogenic, xenogenic, and barrier membrane, such as EMD, collagen, OFD, or an untreated socket. The test groups had synthetic HA, BCP-containing HA, or nanocrystalline HA (NC-HA). Several outcome measures related to healing of the hard or soft tissues after treatment were evaluated. The primary outcome measures were defined related to alveolar bone regeneration. These measurements involved a radiographic (IOPA/CADIA/parallel), histologic, and histomorphometric analysis. The amount of new bone formed and the changes in density from the baseline to several months of follow-up were evaluated. Several studies with the same methods and outcome measures were analyzed and displayed as a graph.

Compared to the previous systematic review \[[@bib30], [@bib31]\], our systematic review focused on evaluating HA bone substitute for the treatment of alveolar bone in cases of alveolar ridge or socket preservation, sinus augmentation, and periodontal bony defect compared to controls (without HA bone substitute) in relation to new bone regeneration on radiographic, histologic, and histomorphometric analysis.

The quality assessment of the included studies resulted in only three studies classified as having a low risk of bias. One study had a moderate and 38 a high risk of bias; thus, their results must be evaluated with caution. The reason for high risk of bias was because several studies lacked an adequate sequence generation, allocation concealment and patient masking, therapist, and statistician. Moreover, most studies did not perform sample size calculation, while definitive sample size calculation was conducted only in 13 of 42 studies. Consequently, insufficient reported data existed to be used further to determine the validity of outcome and estimation.

The new bone regeneration after HA bone substitute grafting was measured as the presence of newly formed bone (histomorphometric), bone density (radiographic), or bone defect fill (radiographic or bone sounding methods). Clinical measurements, such as PPD, CAL, PI, and GI, were performed to evaluate the soft tissue around the defect area. Histologic sections were assessed by descriptive analysis, without statistical analysis.

This systematic review aimed to evaluate the effectiveness of HA bone substitute alone or in combination compared to nonsynthetic graft or an untreated socket. The inter-reader agreement was high (i.e., initial step, κ = 0.968; first step, κ = 0.910, and second step, κ = 0.864), most probably because both readers were well experienced with the HA bone substitute and treatment evaluated in this study. The 95% CI was used to analyze the similar outcome measured data presented in the original studies with different treatment modalities and time to follow-up after treatment. Several methods were chosen in the control groups within the studies found. Control groups existed with an empty untreated socket and treatments with gelatin sponge, guided bone regeneration (GBR) methods, PRP, and EMD. This is the reason for the difficulties in comparing the studies since there was heterogeneity in the control groups. Thus, further evaluation could not be performed in some studies.

The systematic review confirmed that the same material was not always effective when applied in different cases. Some related studies showed that although NanoBone was effective in sinus augmentation, it was not suitable for socket preservation since the socket preservation deals with a special defect and exposure in the oral cavity [@bib2]. In the case of the alveolar ridge, significantly better preservation was achieved with an inorganic bovine containing 10% collagen (Bio-Oss) than with a synthetic bone substitute composed of HA and silicone dioxide (NanoBone). Meanwhile, the autogenous grafts still were considered the golden standard for grafting procedures since they resulted in a high rate of new bone regeneration [@bib63], followed by allogenic demineralized bone matrix \[[@bib2], [@bib63]\]. A particulate autogenous bone combination with β-TCP [@bib23] or HA/β-TCP [@bib76] as well autogenous graft alone for sinus maxillary augmentation resulted in a remarkable amount of newly formed bone after a 5-month healing period. However, the volume of newly formed bone was not significantly affected by adding synthetic bone ceramic to particulate autogenous bone but reduced the high risk of donor site morbidity and lowered the pain [@bib76].

There were many RCTs that established PRP usefulness in the field of tissue regeneration \[[@bib32], [@bib63]\]. Arenaz-Búa et al. [@bib63] found that PRP facilitated and accelerated bone formation in the 3 months postoperatively. The study showed that autograft or allograft combination with PRP resulted in a higher rate of newly formed bone than synthetic particulate HA-silicon dioxide (NovaBone) with PRP after 6 months of follow-up.

Inorganic bovine-derived HA [@bib74] or deproteinized bovine bone (DBB) [@bib7] appeared to be significantly more effective in osteoconduction compared to β-TCP alone or combined with synthetic HA [@bib7] (*P* = 0.001). The histomorphometric analysis showed that new bone formation around the graft particles was similar for BCP and inorganic bovine bone (ABB) \[[@bib67], [@bib73]\] or DBB [@bib69]. No statistical significant difference was noted between BCP and ABB or DBB with regard to newly formed bone in the defect site \[[@bib7], [@bib69]\]. Biphasic synthetic materials consisting of a mixture of HA and TCP were used for reconstruction in implant surgery. Artzi et al. (2008) [@bib95] claimed that an optimum balance of the stable phase of HA and soluble phase of TCP induced increasing new bone regeneration. Synthetic or particulate HA compared to DBB (Bio-OSS) did not show a statistically significant difference to support new bone formation within the sinus cavity \[[@bib8], [@bib22], [@bib68], [@bib75]\]. A significantly higher new bone formation rate was found for natural deproteinized bovine HA (BHA) versus NC-HA after 12 months [@bib70]. DFDBA and HA combined with autogenous bone were biocompatible and allowed osteoconduction. Their values for new bone formation in sinus augmentation were not significantly different. However, both materials were still present after 10 months [@bib6].

The density of bone regeneration using PLGA/HA was significantly less than that of DBB. Clinical assessments demonstrated that PLGA/HA has sufficient characteristics to be used in sinus-lifting surgery [@bib71]. On the contrary, PLGA synthetic polymer scaffolds brought fast resorption rates characteristically, making them difficult to provide adequate mechanical stability for osteoblasts delivered in the graft site [@bib26]. Radiographic results showed that PLGA/HA was able to regenerate bone in the sinus-lift area, but with insufficient quantity and quality to insert endosseous implants. DBB provided greater bone density and equivalent vertical dimension with PLGA/HA grafted bone [@bib71].

HA and β-TCP appear to be safe and may be clinically acceptable in various types of periodontal defects [@bib87]. Combined HA and β/α TCP \[[@bib7], [@bib81], [@bib82]\], whether or not with additional EMD or marginal pedicle periosteum, showed better results in bone defect filling compared to OFD alone or EMD alone. HA plus bioactive glass \[[@bib10], [@bib88]\] was able to ovoid the defect (significant difference, *P* \< 0.05) compared to HA or OFD alone, but DFDBA did not have any statistical differences with HA bone graft at 6 months of follow-up [@bib87]. DFDBA combined with PHA showed the same result as DFDBA [@bib92] alone. DFDBA and synthetic or particulate HA had similar effects on periodontal bony defect treatment since their values were likewise not statistically different \[[@bib87], [@bib96]\]. When regeneration of the periodontium tissue was the desired goal, then DFDBA seemed to be an appropriate material. If only defect fill was the objective, then the choice appeared to be equivalent [@bib96]. The NC-HA bone graft plus collagen membrane demonstrated clinical and radiographic advantages beyond the one achieved by OFD alone and showed a statistically significant difference for percentage of bone fill after 6 months of follow-up [@bib79]. Additional use of NHA after OFD did not reduced the defect depth significantly [@bib89].

There were small changes in the bone level when membrane alone was used. The combination of PHA with barrier membrane (Goretex) [@bib90] or SBC (synthetic bone substitute composed of BCP with 60% HA and 40% β-TCP) with EMD or HA cement (HAC) with a nonbioabsorbable e-PTFE membrane [@bib94] led to more attachment gain and bone fill than synthetic HA alone or a conventional flap [@bib97]. They achieved increased bone fill in the defect site better than synthetic HA alone although the results were not significantly different after 6 months of follow-up.

5. Conclusions {#sec5}
==============

Based on this systematic review, autograft is still considered the best bone grafting material for ridge or socket preservation, sinus augmentation, and periodontal bony defect. HA bone substitute is a good bone graft candidate to reduce the high risk of donor morbidity and evoke less pain, but no significant results were found in the studies. Thus, to overcome the problems in grafting procedures, superior bone substitute with ideal properties for the treatment of choice in alveolar ridge or socket preservation, sinus augmentation, and periodontal bony defect must be developed.
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